\
&
Contact us
\
&
Contact us
Published on | 8 months ago
Programmes Horizon Europe HorizonEU L+F Digital EuropeOn 20 december 24 the President of the European Commission Ursula von der Leyen and the President of the Swiss Confederation Viola Amherd confirmed the completion of negotiations on a broad package of agreements that aim to deepen and expand the EU-Switzerland relationship. More detials on this press release.
A transitional arrangement allows researchers and innovators in Switzerland to participate in almost all calls for proposals of Horizon Europe, the Euratom programme and Digital Europe, from the 2025 programme year onwards. They can apply as beneficiaries in almost all calls. The budget of the Swiss partner must be included in the total grant amount that the consortium is requesting from the EU.
Though be aware of the following.
This webpage of SERI (the Swiss State Secretariat for Education, Research and Innovation) gives details about the transitional measures, including an elaborated FAQ page.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space AI Continent Cybersecurity
The European Commission has opened a call for evidence to collect research and best practices on how to simplify its legislation, especially when it comes to data, cybersecurity and artificial intelligence (AI). This initiative is part of the Commission’s simplification agenda and efforts to create a more favourable business environment, by... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
